Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
Linepharma’s oral abortion drug Mefeego (mifepristone/misoprostol) was backed for approval by a key health ministry panel on April 21. The drug is expected to receive the final green light by the end of May to become Japan’s first abortion pill.…
To read the full story
Related Article
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Public Comments 2 to 1 in Favor of Approving Abortion Pill: MHLW
March 27, 2023
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…